Swiss biotech firm halts trial of heart drug

11/8/2004 | Bloomberg

Actelion plans to tell investors today that it stopped the phase III clinical trial of Veletri, a proposed treatment for acute heart failure, because the study failed to show effectiveness. The study's steering committee recommended stopping the trial because 1,300 patients showed no statistically significant results. No safety issues surfaced in the trial, the firm said.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
Catheter Engineer
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
MANAGER MEDICAL GAS COMPLIANCE AND SAFETY
Matheson Tri-Gas, Inc.
Houston, TX
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations